Bulk Pharmaceutical API Sources for KYZATREX

Bulk Pharmaceutical API Sources for KYZATREX

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		65157
ABI Chem		AC1L22PV
ChemMol		49406046
AKos Consulting & Solutions		AKOS016010255
Chembase.cn		178187
Alsachim		3463

Bulk Active Pharmaceutical Ingredient (API) Sources for: KYZATREX

Last updated: July 28, 2025

---

Introduction

KYZATREX (Kynmobi) is a proprietary pharmaceutical product primarily used in the treatment of Parkinson’s disease. Its formulation comprises apomorphine hydrochloride, a potent dopamine agonist, delivered via sublingual film. As a specialty medication, the sourcing of high-quality Active Pharmaceutical Ingredients (APIs) is critical to ensure efficacy, safety, and regulatory compliance. This report examines the primary sources for bulk API procurement relevant to KYZATREX, emphasizing market dynamics, supplier identification, regulatory considerations, and key sourcing strategies applicable to pharmaceutical manufacturing stakeholders.

---

Overview of Apomorphine Hydrochloride as the API for KYZATREX

Chemical Profile:
Apomorphine hydrochloride is a potent dopamine agonist with a complex synthesis process involving multiple chemical steps, typically starting from natural or synthetic morphine derivatives. Its pharmacological profile necessitates strict control over purity, stability, and bioavailability parameters.

Therapeutic Use:
Administered primarily via sublingual films for Parkinson’s disease management, apomorphine’s rapid onset of action and high potency make the API sourcing process particularly sensitive to quality standards.

Regulatory Landscape:
API suppliers must comply with stringent global standards, including the US Pharmacopeia (USP), European Pharmacopoeia (EP), and ICH guidelines, to meet regulatory approvals in markets like the US (FDA), EU (EMA), and Japan (PMDA).

---

Major API Producers for Apomorphine Hydrochloride

1. Established Global Pharma API Manufacturers

Several global pharmaceutical companies with a specialized focus on dopamine agonists and neurological APIs dominate the apomorphine supply landscape. These include:

a. Sun Pharmaceutical Industries Ltd.
A major Indian pharmaceutical manufacturer with extensive API capabilities, Sun Pharma produces apomorphine hydrochloride for global markets. Their manufacturing facilities adhere to cGMP standards, providing high-purity APIs with comprehensive quality documentation.

b. Granules India Ltd.
Another Indian API supplier with scalable production of dopamine receptor agonists, including apomorphine. Granules India emphasizes cost-effective manufacturing, making it attractive for generic formulations, but compliance with regulatory standards remains a priority.

c. Ferring Pharmaceuticals
While primarily known for biologics and specialized products, Ferring manufactures dopaminergic APIs for niche markets and collaborates on neurological indications, potentially supplying custom or high-quality APIs for licensed products.

d. Sigma-Aldrich (Merck KGaA)
A leader in chemical synthesis and laboratory reagents, Sigma-Aldrich provides research-grade apomorphine hydrochloride, which can serve as reference standards or the basis for bulk synthesis in pharma-grade manufacturing.

2. Chinese and Indian API Manufacturers

The rapid growth of API manufacturing capacity in Asia, especially India and China, has expanded available sources for apomorphine hydrochloride.

a. Hubei Yitai Pharmaceutical Co., Ltd. (China)
Specialized in neurological APIs, offering competitive pricing and diverse product portfolios. Regulatory compliance and batch-to-batch consistency are key factors to verify.

b. Kent Pharma Ltd./K-shell Healthcare (India)
Part of a broader manufacturing network with cGMP-certified facilities providing apomorphine hydrochloride. They often supply APIs suitable for commercial production of neurological drugs.

3. Contract Manufacturing Organizations (CMOs)

CMOs with established capabilities in complex chemical API synthesis are increasingly pivotal:

a. Cambrex Corporation
Provides custom synthesis of apomorphine hydrochloride, with an emphasis on API purity, process optimization, and regulatory support.

b. Dr. Reddy’s Laboratories
Having expanded into complex APIs, Dr. Reddy’s offers tailored API manufacturing services, including for dopaminergic compounds, aligned with regulatory standards.

---

Sourcing Strategies and Considerations

Quality Compliance and Regulatory Certification:
Suppliers must demonstrate compliance with cGMP standards, possess requisite regulatory approvals (e.g., FDA inspection reports), and supply comprehensive documentation including Certificates of Analysis (CoA), Certificates of Suitability (CEP), or Drug Master Files (DMF).

Scientific and Technical Capabilities:
Manufacturers must have robust synthetic pathways for apomorphine hydrochloride, scalable production capacity, and strict quality control measures to ensure API consistency and stability.

Cost and Supply Chain Reliability:
Cost-effectiveness remains significant given large-volume procurement, but supply chain resilience and contingency planning are equally critical, especially amid global disruptions like pandemics or geopolitical issues.

Intellectual Property & Patent Landscape:
Though apomorphine itself is an off-patent chemical, formulations such as KYZATREX’s proprietary film delivery system may carry patent protections. API sourcing should align with legal and IP considerations, ensuring supplier access to licensed or patent-expired APIs.

---

Regulatory and Quality Assurance Implications

Manufacturers and brand owners seeking to develop KYZATREX or similar formulations must verify API supplier credentials, review audit reports, and conduct independent testing or validation. Certain markets require ongoing supplier qualification processes, including site inspections, stability testing, and sample analysis.

Furthermore, global trade of APIs must navigate export/import regulations, tariffs, and country-specific requirements, emphasizing the importance of strategic sourcing partnerships rooted in compliance and quality assurance frameworks.

---

Regional and Market-Specific API Sourcing Dynamics

• North America & Europe:
  High regulatory standards and established supply chains favor partnerships with proven, certified suppliers from EU or US-based manufacturers, or certified CMOs with proven regulatory track records.

• Asia-Pacific:
  Cost advantages and expanding manufacturing capacity make Asian suppliers attractive; however, larger pharmaceutical entities often conduct comprehensive audits and quality validations before procurement.

• Emerging Markets:
  Limited infrastructure and regulatory environments may pose risks; thus, sourcing here demands rigorous qualification protocols.

---

Future Trends in API Sourcing for Parkinson’s Disease Drugs

The evolving landscape sees increasing reliance on contract manufacturing, with a focus on high-potency, complex APIs. Innovations in chemical synthesis and process intensification may reduce costs and lead times. Digital quality monitoring and supply chain transparency are set to enhance API sourcing reliability.

The trend towards sourcing from multiple suppliers to diversify risk and ensure supply continuity is prominent, especially for critical APIs like apomorphine hydrochloride. Additionally, efforts by government and industry consortia to establish API manufacturing clusters aim to boost supply resilience.

---

Key Takeaways

• High-Quality Compliance is Non-Negotiable: Suppliers must be certified with strong regulatory track records, especially for neurological APIs such as apomorphine hydrochloride used in KYZATREX.

• Asian API Manufacturers Are Key Players: Indian and Chinese firms significantly contribute to global apomorphine supply, offering cost-effective options with appropriate validation.

• Strategic Diversification Is Essential: Relying on multiple sources minimizes supply risks and ensures consistent production for sensitive formulations.

• Integrated Supply Chain Management Improves Reliability: Close oversight, qualification, and transparent communication with API suppliers mitigate risks related to quality, delivery, and regulatory compliance.

• Regulatory Alignment and Documentation Are Critical: Proper documentation, including DMFs and COAs, streamline approval processes and facilitate global market access.

---

FAQs

1. What are the primary challenges in sourcing apomorphine hydrochloride APIs?
Challenges include ensuring consistent quality, navigating complex regulatory requirements, managing supply chain disruptions, and verifying supplier compliance with cGMP standards.

2. Can generic suppliers meet the quality requirements for KYZATREX’s API?
Yes, provided they have the necessary certifications, validated manufacturing processes, and quality assurance protocols aligned with regulatory standards like FDA or EMA.

3. How does geographic location influence API sourcing for Parkinson’s drugs?
Geography affects regulatory oversight, manufacturing costs, lead times, and risk exposure to disruptions. Established markets prioritize certified Western suppliers, while Asia offers cost advantages with rigorous qualification procedures.

4. What role do CMOs play in the supply of apomorphine hydrochloride?
CMOs offer scalable, customized manufacturing capabilities, often specializing in complex chemical syntheses, thereby providing flexible, validated supply options for pharmaceutical companies.

5. What emerging trends could impact API sourcing for KYZATREX?
Advancements in process chemistry, digital quality management, supply chain diversification, and global manufacturing alliances are shaping future API procurement strategies, increasing resilience and quality assurance.

---

References

[1] US Pharmacopeia. (2022). Monograph: Apomorphine Hydrochloride.
[2] European Pharmacopoeia. (2021). Monograph: Apomorphine Hydrochloride.
[3] ICH Guidelines for Good Manufacturing Practices. (2020).
[4] FDA Guidance for Industry: Quality Specifications for Pharmaceutical APIs. (2019).
[5] Industry Reports on API Manufacturing Trends (2022).

---